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Angiogenesis is the natural and physiologic process of growing blood vessels from pre-existing ones.
Pathological angiogenesis occurs when the precise balance of all the molecular pathways that regulate
angiogenesis is disrupted, and this process is a critical step in many diseases, including cancer. A limited
number of antiangiogenic synthetic drugs have been developed. However, due to toxicity and side effects
issues, the search for alternative to existing drugs is ongoing. In this sense, natural molecules obtained
from plants or macrofungi, have demonstrated extraordinary potential in the treatment of angiogenesis-
related pathologies, specially taking into consideration its absence or very low toxicity, when compared
to synthetic drugs. Using natural compounds as potential angiogenesis modulators is thus a promising
ﬁeld of research, supporting the creation of novel therapies able to reduce the use of drugs and asso-
ciated side effects. In this review, the current status of antiangiogenic drugs and the wide variety of
natural extracts and molecules with antiangiogenic capacities, as well as the angiogenesis molecular
pathways and therapeutic targets, are presented. Finally, the challenges that need to be overcome in
order to increase the use of natural compounds for clinical purposes are discussed.
© 2017 Elsevier B.V. All rights reserved.1. An overview of angiogenesis
Angiogenesis is a biological process through which there is the
formation of new blood vessels from pre-existing ones and occurs
normally in the body under normal physiological conditions [1e3].
Angiogenesis naturally occurs during fetal development, tissue
regeneration, wound healing and in the female reproductive cycle
[1e4].
The trigger for normal angiogenesis is usually the detection of
low levels of oxygen (hypoxia) by speciﬁc sensing mechanisms, in
poorly perfused tissues, which stimulates the formation of new
blood vessels to comply the cell metabolic requirements [5].Abreu), iferreira@ipb.ptAlternatively, physiological angiogenesis is also triggered by me-
chanical tissue stretch [6].
Angiogenesis occurs in several steps, although some of these
events may temporally overlap. The ﬁrst step is the release of
proteases that promote enzymatic degradation of the capillary
basement membrane that triggers the migration of endothelial
cells to the interstitial space and subsequent proliferation in cord-
like form (sprout). The developing sprout elongates by proliferation
of more endothelial cell and the two developing sprouts eventually
fuse and form the lumen. Blood ﬂow is then established and the
newly formed blood capillary is stabilized through basement
membrane deposition, pericyte recruitment and smooth muscle
layer formation [7].
Although angiogenesis is a naturally occurring event, abnormal
growth of new blood vessels is known to be involved in the
development of various diseases including cancer, inﬂammation,
eye illnesses, retinopathy, rheumatoid arthritis, among others [2,8].
Additionally, inadequate vessel preservation or growth may lead to
ischemia causing myocardial infarction, stroke, and
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some diseases, including ischemic heart disease and peripheral
arterial disease, the objective is to stimulate angiogenesis, while in
other pathologies, including cancer, the goal is to inhibit abnormal
angiogenesis.
The importance of angiogenesis in tumor development and
metastases in cancer is well established. For tumor growth to occur,
large amounts of nutrients and oxygen are necessary and, to
overcome this situation, angiogenesis plays an important role in
tumor development since it guarantees the survival of cells.
Angiogenesis also facilitates the dissemination of tumor cells
through the blood stream, achieving distant organs in the form of
metastases [9,10]. Tumor angiogenesis occurs when tumor cells, as
well as inﬂammatory cells aggregated to the tumor, produces
angiogenesis factors that trigger the rapid development of angio-
genesis [7,11]. Inhibition of tumor angiogenesis can thus decrease
the blood ﬂow, required for tumor development, and tumor cell
growth would be ceased due to lack of nutrients and growth factors
needed to support the formation of newly formed vessels [12].
Previous studies have identiﬁed and characterized numerous
angiogenesis factors, both activators and inhibitors, which regulate
angiogenesis. The most extensively studied angiogenesis regulators
is vascular endothelial growth factor (VEGF) and the respective
membrane receptors, mainly VEGFR-2, as they are recognized to
play a major role in regulating physiological and pathologicalangiogenesis [13]. The ﬁrst treatment that targeted tumor angio-
genesis was monoclonal antibody bevacizumab, which acts by
interacting and blocking VEGF interaction with its receptor. An
alternative strategy to target VEGFR-2 is using small molecules like
tyrosine kinase inhibitors (TKIs). This strategy resulted in the ﬁrst
clinically approved small molecule-like drugs that targeted tumoral
angiogenesis: sunitinib and sorafenib [14,15]. VEGFR-2 inhibition is
still being actively studied; it is considered an important strategy
for angiogenesis inhibition [16] and towards the discovery of new
anticancer drugs [17]. Many other angiogenesis therapeutic targets
are currently being studied.
Natural compounds, present in medicinal and/or nutritional
plants as well as in macrofungi sources, have stimulated a great
interest from the pharmaceutical industry. Different natural com-
pounds such as phenolic compounds, alkaloids, terpenoids among
others, have shown strong antiangiogenic effects and can be
considered as viable options to develop new strategies or drugs for
targeting pathological angiogenesis. The low or even absent
toxicity of these active compounds, make them an attractive
alternative for human health maintenance. Chemoprevention is a
promising anticancer approach with reduced secondary effects in
comparisonwith synthetic drugs [18]. Chemoprevention consists in
using other active molecules, such as naturally occurring anticancer
agents, to inhibit or reverse some processes of carcinogenesis,
including pathological angiogenesis [19]. The advent of diseases
A. Ribeiro et al. / Cancer Letters 415 (2018) 86e10588can thus be substantially prevented through new dietary habits,
and the increased consumption of natural products have long been
known to have a chemopreventive effect.
In the next section (Section 2) a survey of selected angiogenesis
pathways and therapeutic targets will be presented, with emphasis
on molecular mechanisms that have been targeted by natural
molecules or natural sources. Section 3 will then review the current
status of drugs used against angiogenesis, while Section 4 will
provide an extensive review on the state of the art of known natural
sources with antiangiogenic activity. Finally, Section 5 will focus on
the challenges that natural products face to be used at a wider scale
formedicinal purposes, thus as potential substitutes for the existing
drugs.2. Angiogenesis molecular pathways and therapeutic targets
The formation of new blood vessels is controlled by various
angiogenic factors that act by triggering the signaling pathways
leading to blood vessels formation and repairing. Other angiogenic
factors may act by promoting the inhibition of angiogenesis, thus
interfering with the formation of new blood vessels. The activation
and inhibition effects of these angiogenetic factors are normally
balanced so that blood vessels only form when needed by the or-
ganism. These angiogenic factors may be classiﬁed in different
groups including growth factors, matrix metalloproteinases (MMP-
2 and MMP-9), cytokines, transcription factors, arachidonic acid
derivatives and cell cycle related proteins, among others [1]. All of
these angiogenic factors may be regarded as potential therapeutic
targets, for treatment of conditions involving pathological angio-
genesis. Some of the most widely studied angiogenic factors, as
potential therapeutic targets, include vascular endothelial growth
factor (VEGF), ﬁbroblast growth factors (FGF), platelet derived
growth factor (PDGF), matrix metalloproteinases, tumor necrosis
factor alpha (TNF-a) and hypoxia-inducible factor (HIF-1), just to
name a few [20]. Therapeutic treatments that target angiogenic
factors have in fact already been developed, with the notable
example of antibodies and small TKIs against VEGF and respectiveTable 1
Drugs currently in clinical use that affect angiogenesis.
Drug Mode of action Appro
Bevacizumab
(Avastin)
VEGF Antibody CRC, N
Cabozantinib
(Cabometyx)
RTK Inhibitor
(VEGFR, c-Met)
MTC; R
Lenalidomide
(Revlimid)
VEGF expression inhibitor Multip
Pazopanib
(Votrient)
RTK Inhibitor
(c-KIT, FGFR, PDGFR and VEGFR)
RCC, S
Ramucirumab
(Cyramza)
VEGFR Antibody GEJA,
Regorafenib
(Stivarga)
RTK Inhibitor
(VEGFR, Tie)
CRC, G
Sorafenib
(Nexavar)
RTK Inhibitor
Multi-RTK inhibitor
RCC, H
Sunitinib
(Sutent)
RTK Inhibitor
(Kit,VEGFR-2 and PDGFR inhibitor)
GIST, R
Thalidomide
(Immunoprin)
TNF-a and IL-6 expression inhibitor,
NF-kB and COX-2 inhibitor
Multip
Vandetanib
(Caprelsa)
RTK Inhibitor
(VEGFR-2, EGFR and RET)
MTC
c-KIT e Tyrosine-Protein Kinase Kit; c-Met e Tyrosine-Protein Kinase Met; COX-2 e Cyc
FGFR e Fibroblast Growth Factor Receptor; GEJA e Gastro-Esophageal Junction Adenocar
IL-6 e Interleukin-6; MTC e Medullary Thyroid Cancer; NF-kB e Nuclear Factor Kappa B
Receptor; RCC e Renal Cell Carcinoma; RET e Rearranged During Transfection; RTK e R
TNF-a e Tumor Necrosis Factor e a; VEGF e Vascular endothelial Growth Factor; VEGFRreceptors (Table 1). A brief description of some of the most studied
angiogenic factors, and the respective molecular pathway, will be
presented, highlighting the pathways that have already been tar-
geted by natural compounds and sources. Fig. 1 presents an over-
view of the signaling pathways involved in angiogenesis, which
were targeted by different natural molecules.2.1. Receptor tyrosine kinase (RTK)-mediated growth factors
Growth factors like VEGF have received great attention, as well
as their respective membrane receptor tyrosine kinase (RTKs):
VEGFR-1, VEGFR-2 and VEGFR-3 [21]. Recent studies revealed that
VEGF is the major mediator of endothelial cells angiogenesis
signaling pathways, and is considered themain signal transducer in
angiogenesis regulation [3,12]. VEGF acts by interacting with the
extracellular domain of the respective RTKs, present in the mem-
brane of endothelial cells. This interaction promotes VEGFR
dimerization and activates the intracellular domain tyrosine kinase
activity of VEGF receptors. The intracellular domain then phos-
phorylates and activates speciﬁc proteins involved in angiogenesis
signaling pathways and this process eventually leads to stimulation
of endothelial cell migration, proliferation and vascular formation
[6]. For the development of new angiogenic inhibitors, the inhibi-
tion of VEGFR-2 has attracted great attention, since several
monoclonal antibodies and TKIs have shown that it was possible to
stop tumor angiogenesis, by blocking interaction between VEGF
and his receptor VEGFR-2, present in the membrane of endothelial
cells [12].
Another growth factor involved in angiogenesis is the platelet-
derived growth factor (PDGF) that acts by activating speciﬁc RTKs
proteins (PDGFRa and PDGFRb), present in the membrane of
endothelial cells. PDGF stimulates pericyte recruitment, a process
that is fundamental on blood vessel maturation [22], resulting in
the stabilization of the capillary wall [23]. Moreover, has been
shown that PDGF and VEGF work symbiotically in order to stimu-
late formation and stabilization of the new blood vessels [22].ved indications Year of approval References
SCLC, RCC, breast cancer 2004 [4]
CC 2011 [174]
le Myeloma 2004 [114]
TS 2009 [175]
NSCL 2014 [176]
IST 2012 [177]
CC; MTC 2005 [14]
CC 2006 [15]
le Myeloma 2006 [178]
2011 [179]
looxygenase-2; CRC e Colorectal Cancer; EGFR e Epidermal growth factor receptor;
cinoma; GIST e Gastrointestinal Stromal Tumors; HCC e Hepatocellular Carcinoma;
; NSCL e Non-Small-Cell Lung Carcinoma; PDGFR e Platelet Derived Growth Factor
eceptor Tyrosine Kinase; STC e Soft Tissue Carcinoma; Tie e Angiopoietin receptor;
e Vascular Endothelial Growth Factor Receptor.
Fig. 1. Main molecular pathways involved in angiogenesis and that were targeted by natural molecules. Akt e Protein Kinase B; Ang-1 e Angiopoietin 1; CDK6 e Cyclin dependent
kinase 6; Ck2 e Casein Kinase II; COX-2 e Cyclooxygenase-2; eNos e Endothelial nitric oxide synthase; ERK e Extracellular signal-regulated kinase; FGF e Fibroblast growth factor;
FGFR e Fibroblast growth factor receptor; HIF-1 e Hypoxia-inducible factor; Hsp90 e Heat stock protein; IKK e Inhibitor of kappa B; IL-1 e Interleukin-1; IL-6 e Interleukin-6; LOX-
5 e 5-Lipoxygenase; MMP2 e Matrix metalloproteinase 2; MMP9 e Matrix metalloproteinase 9; NF-kB e Nuclear factor kappa B; PDGF e Platelet derived growth factor; PI3K e
Phosphoinositide 3-kinase; PKC e Protein kinase C; Tie e Angiopoietin receptor; TNF-a e Tumor necrosis factor-a; TSP-1 e Thrombospondin-1; VEGF e Vascular endothelial growth
factor; VEGFR-2 e Vascular endothelial growth factor receptor 2.
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is the ﬁbroblast growth factor (FGF), known to be expressed by
tumor cells [1]. FGF can be directly related with tumor cells pro-
liferation, speciﬁcally the FGF-2 isoform, known to induce endo-
thelial cell proliferation and migration by interacting with speciﬁc
RTKs present in the membrane of endothelial cells [11,24]. Overall,
FGF plays an important role in angiogenesis and evidence suggest
the existence of cross talk and synergism between FGF and other
growth factor pathways [25].
Finally, angiopoietin receptor-2 (Tie-2) is a transmembrane
tyrosine kinase receptor, which binds to angiopoietins being also
involved in regulating angiogenesis, among other cell activities.
Angiopoietins are growth factors required for the formation of
blood vessels, and Angiopoietin-1 (Ang-1) in known to down-
regulate nuclear factor kappa B (NF-kB) complex, by binding to Tie-
2 membrane receptor, via disruption of the IKK complex [26].2.2. Matrix metalloproteinases
Matrix metalloproteinases (MMP) are proteinases participating
in extracellular matrix degradation, a normal physiological process
that is crucial in several biological events such as embryogenesis,
cell proliferation, apoptosis, but also in angiogenesis [25]. Several
MPPs were shown to be involved in pathological processes, for
example in cancer development and metastasis, by promoting
dysregulation of the basement membrane composition, thus facil-
itating apoptosis [27e30]. Speciﬁcally, MMP-2 and MMP-9 (also
known as Gelatinase A and B, respectively) digest denatured col-
lagens and were related to the cancer invasion process, as tumor
cells must cross the collagen-rich basement membrane of blood
vessel walls, in order to grow to distant locals from the primary
tumor [27,28]. As an example of this process, the MMP-9 presents
an important role in the pathological angiogenesis in malignant
glioma [31] and diabetic retinopathy [30].
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Cytokines are a diverse group of low molecular weight proteins
that are involved in a number of cell signaling pathways that
regulate as diverse cellular events as the immune response,
inﬂammation and cancer, among others. It has been long recog-
nized that the immune response is tightly associated with the
endothelial process of angiogenesis, and that this association is
implemented by way of cytokines that are produced during the
immune response [32]. Endothelial cells have also been recognized
for having the ability to generate abundantly cytokines [33]. These
substances inﬂuence the intensity of the angiogenic response
induced essentially during inﬂammation. The angiogenic effects
attributed to cytokines has also been related with the ability to
prime endothelial cells for the subsequent action of VEGF [34].
The protein cytokine interleukin-6 (IL-6) is involved in several
biological activities, including hematopoiesis, immune responses
and inﬂammation. This protein is secreted mainly by immune cells
[35,36] and is hardly detectable under normal physiological con-
ditions [36], although its induced biological responses are impor-
tant in controlling inﬂammation and in maintenance of tissue
homeostasis [35]. However, levels of IL-6 are signiﬁcantly changed
in pathological conditions; in particular, in inﬂammatory bowel
disease, autoimmune acute phenomena, myeloma and arthritis
[36], and part of IL-6 inﬂuence is by inducing leukocytosis and
angiogenesis [37].
Other cytokine that also plays an important action in inﬂam-
matory diseases is interleukin-1 (IL-1), being a potent mediator in
response to injury and infections [38]. IL-1 is mainly produced by
myeloid cells and initiates and propagates inﬂammation mainly by
inducing a local network of cytokines [30]. Pro-inﬂammatory me-
diators, including IL-1, have recently been shown to play an
important role in tumor-mediated angiogenesis, and IL-1 inhibition
is now considered as a potential target for anti-cancer therapy [39].
Tumor necrosis factor a (TNF-a) is an inﬂammatory cytokine,
normally found in high concentrations in tissues subject to
inﬂammation processes, being primarily produced by activated
macrophages, T lymphocytes and natural killer cells [40]. Some
studies reported that TNF-a is commonly found along the joints,
leading to production of several pro-inﬂammatory effects, thus
contributing to joint degradation [41,42]. Furthermore, TNF-a plays
an important role the NF-kB signaling pathway initiation [43].
In general, in normal plasma concentrations, IL-1, IL-6 and TNF-
a act together in promoting pathogens elimination, through
increasing the body temperature (fever) and leukocytosis [36].
However, when found in high concentrations, they constitute ac-
tivators of severe and acute inﬂammatory and immune responses,
which have been associated with angiogenesis activation [39].
These cytokines have thus been recognized as potential targets for
therapeutic antiangiogenic interventions [36,44].
2.4. Transcription factors
Transcription factors are proteins that are involved in gene
expression regulation, by binding to speciﬁc deoxyribonucleic acid
(DNA) sequences. Hypoxia-induced factor (HIF-1) is a transcription
factor that plays an important role in the organism response to low
oxygen concentrations scenarios (hypoxia), by regulating the
expression of genes that facilitate adaptation and survival of cells in
hypoxia situations [45,46]. In developing embryos, angiogenesis is
a key process that is largely controlled by HIF-1 mediated hypoxia.
The release of HIF-1 stimulates the expression of angiogenic factors,
including VEGF. However, HIF-1 is also the main factor responsible
for increasing the vascularization of hypoxic areas, which occur in
ischemia situations and in tumor growth [46]. Although HIF-1 isessential for the regulation of angiogenesis, it also promotes sur-
vival and proliferation of cancer cells, due to its angiogenic prop-
erties [47].
Nuclear factor kappa B (NF-kB) is a protein complex that acts as
a transcription factor that is involved in several physiological pro-
cesses including immune and inﬂammatory responses [48]. The
NF-kB family is constituted by p65, RelB, c-Rel, p50 and p52 sub-
units, which act as homo or hetero-dimers [49]. Typically, the NF-
kB complex remains inactive in the cytosol, by forming a protein
complex with IkB (inhibitor of kappa B). By external stimulation,
IkB is phosphorylated and targeted for degradation, thus freeing
and enabling NF-kB gene expression activity [49,50]. However,
dysregulation of NF-kB activity, plays a critical role in angiogenic,
inﬂammatory and autoimmune diseases as well as in the cancer
process [30]. NF-kB is involved in oncogenesis and tumor cell
resistance, due to inadequate gene expression of several factors
involved in apoptosis suppression, cell adhesion and proliferation
[49]. The kinase responsible for the phosphorylation of IkB is IkB
kinase-b (IKK-b), which is part of the IKK complex [51]. IKK-b is thus
considered an angiogenesis inducer and is also regarded as a po-
tential antiangiogenic target [51,52].
2.5. Cyclooxygenase 2 (COX-2) and 5-lipoxygenase (LOX-5)
Arachidonic acid-derived lipid mediators (AA-DLMs) are
involved in the inﬂammation process and are biosynthesized by
pathways dependent on cyclooxygenase (COX) and lipoxygenase
(LOX) enzymes. COX-2 is a key enzyme in the biosynthesis of
prostaglandins, a family of AA-DLMs that include Prostaglandin E2
(PGE2), Prostaglandin D2 (PGD2), Prostaglandin F2a (PGF2a),
Prostaglandin I2 (PGI2) and prostaglandin A2 (PGA2), [53,54].
Additionally, 5-lipoxygenase (LOX-5) participates in the conversion
of arachidonic acid to leukotrienes, the second largest family of AA-
DLMs [55]. COX2 and LOX-5 mediated biosynthesis of AA-DLMs,
plays an important role in the inﬂammation process, which occur
in different conditions including rheumatoid arthritis, neuro-
inﬂammation and psoriasis [53e55]. Due to the contribution of
COX-2 and LOX-5 in the inﬂammatory process, there is a large in-
terest in the use of new drugs as inhibitors of these oxygenase
enzymes [56,57]. Recently, the upregulation of COX-2 was reported
in situations where antiangiogenic therapies were applied, specif-
ically in treatment with anti-VEGFR-2 antibodies and sunitinib.
When COX-2 is inhibited, the production of PGE2 levels diminish
and the anti-VEGFR2 therapy efﬁciency improves. Following COX-2
inhibition, a reduction of tumors inﬁltration by cancer-associated
ﬁbroblasts is observed. Clinical investigations are ongoing to
investigate the cooperative inhibition of COX-2 and VEGF-signaling
capable to block tumor angiogenesis [58].
2.6. Cell cycle related proteins
The complexity of angiogenesis provides many targets for
therapeutic intervention and a number of proteins, which are
involved in the cell cycle complex machinery, have been studied as
angiogenic modulators. Cyclin dependent kinases (CDKs) are
serine/threonine kinases, which belong to the core cell cycle ma-
chinery, and exert their kinase activity when bounded to cyclins
[59]. Cyclin D1 is an important cycle progression regulation and can
also function as a co-transcriptional regulator by forming a complex
with CDK6 kinase [60]. Overexpression of cyclin D1 has been shown
to lead to accelerated G1 progression and chromosome instability
in several cell types [61], and some studies relate the amount of
cyclin D1 with cancer manifestation [62]. CDK6-cyclin D1 complex
was also shown to be involved in tumor angiogenesis, through
regulation of VEGF synthesis [62]. Also, cell cycle inhibitor proteins,
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binding and inhibiting CDK-cyclin complexes [63], thus promoting
cell cycle arrest, growth arrest and differentiation or senescence, in
response to various stimuli [64]. Besides its ability to inhibit the
activity of cyclin-dependent kinase, p21 also operates as a mediator
of p53 tumor suppressor activity. Also, expression of p53 in cells
can induce cell growth arrest through transcriptional activation of
p21 [65]. Both p21 and p53 up-regulation can thus be viewed as
potential therapeutic routes for tumor angiogenesis inhibition [66].
Heat shock protein 90 (Hsp90) is an essential adenosine
triphosphate (ATP) dependent molecular chaperone, and is abun-
dantly expressed in eukaryotic cells [67,68]. Hsp90 plays an
important role in various cellular processes, among which cell cycle
control, cell survival and different signaling pathways can be cited
[69]. Hsp90 overexpression has been related to tumor cells survival,
in adverse conditions such as lack of nutrients, hypoxia and acidosis
[68]. Hsp90 has also been related to tumor angiogenesis, and recent
studies have suggested that Hsp90 inhibitors promote angiogenesis
inhibition, by affecting the PI3K/Akt/eNOS (phosphoinositide 3-
kinase/protein kinase B/endothelial nitric oxide) signal trans-
duction pathway in endothelial cells, as well as through down-
regulation of VEGFR-2 expression [70].
Akt (also known as protein kinase B) is another serine/theronine
kinase that has been recognized to be involved in the signaling
pathways leading to cell proliferation, cell growth and survival [71],
and the dysregulation of this kinase is related with various human
diseases including diabetes, cancer and cardiovascular diseases
[72]. Akt is activated by interacting with Hsp90, thus it is also
recognized as a potential target in abnormal angiogenesis [71]. Cell
division cycle 37 (Cdc37) protein has shown signiﬁcant inﬂuence in
cell proliferation, mainly in cancer cells [73]. Cdc37 promotes its
function by forming complexes with oncogenic protein, including
Hsp90, Raf1 and cyclin dependent kinase 4 (CDK4) [73]. Thereby,
several authors have indicated Cdc37 as being involved in Hsp90
activation and subsequent tumor angiogenesis induction through
Akt activation [74,75].
Extracellular signal-regulated kinase (ERK) is another serine/
threonine kinase, which is a member of the mitogen-activated
protein kinases (MAPK) kinase family that is known to be
involved in various cellular functions, and in different cell types
[76]. ERK is activated by different growth factors and cytokines, and
have been reported to play pivotal roles in many aspects of cell
function such as proliferation, differentiation and survival [77].
Phosphorylation of the ERK is induced by VEGF and, in this phos-
phorylated form, ERK is known to induce angiogenesis in endo-
thelial cells. Inhibition of ERK was shown to prevent endothelial
sprouting, although not initial artery differentiation. These studies
implicate ERK as a speciﬁc effector of VEGFR signaling pathway, in
the induction of angiogenic genes during sprouting [78].
2.7. Other intracellular angiogenic modulators
The most antique antiangiogenic factor to be identiﬁed was
thrombospondin-1 (TSP-1). TSP-1 is an endogenous inhibitor and
its antiangiogenic ability was related to the capability of interacting
with FGF-2, thus preventing interaction between FGF-2 and the
soluble heparin or endothelial cells heparin sulfate proteoglycans
[79], thereby avoiding the progression of the angiogenic process.
Angiostatin and endostatin were subsequently identiﬁed and both
participate in antiangiogenic processes. Angiostatin is polypeptide
that occur naturally in various animal species, including humans. It
is classiﬁed as endogenous angiogenesis inhibitor and your ca-
pacity is related with downregulating VEGF expression blocking
one the major vascular growth factors [80,81]. Like angiostatin,
endostatin is also a polypeptide. Endostatin is derived fromcollagen XVIII (created by digestion of the C terminal fragment of
collagen) [82,83], it participates in inhibition of endothelial cells
proliferation inhibiting many steps of angiogenesis [82,84]. The
inhibition of VEGF, metalloproteinases and cyclin D1 is the most
important ways that endostatin act for block the angiogenesis
process [85]. Both proteins, angiostatin and endostatin, are
expressed in pathological situations, such as pathological angio-
genesis, and plays a critical role in inhibition of primary metastatic
tumor growth [83].
The interferons are another molecules that act as angiogenesis
inhibitor and can be classiﬁed in two classes: interferon-alpha (IFN-
a) and interferon-beta (IFN-b) and both are cytokines. These in-
terferons were one of the ﬁrst to be used in association with
chemotherapeutic agents in clinical trials of human tumors [86].
Thus, the IFN-a has been recognized as powerful angiogenic in-
hibitor [87] and though that IFN-a potential in angiogenic pro-
cesses is mainly attributed to inhibition of FGF, decrease VEGF gene
expression and downregulation of interleukin-8 production
[87,88]. Additionally, the IFN-a has also direct effects on EC avoiding
of their proliferation and migration [87]. Relatively to the IFN-b is
described with capacities to decrease MMP-2 production through
suppressing gene expression and down relate FGF expression [86].
Integrins belongs to heterodimeric transmembrane receptors
(composed by an a- and a b-subunit) mediated cell-extracellular
matrix adhesion [89] and coordinate a large amount of cellular
activities in response to the extracellular environment [89]. Integ-
rins receptors are important in angiogenic development [90] and,
actuality, integrins represent an important target for pharmaceu-
tical agents in order to create innovative ways for angiogenesis and
metastatic control [91].
Neovastat is a product derived from shark cartilage (Æ-941) [92]
and the main functionality is related with inhibition of two main
mechanism of angiogenesis activation, in speciﬁc, VEGF (competes
with VEGF for binding to VEGFR and inhibit the receptor activation)
and MMP [92,93]. Additionally, the neovastat also shows a signiﬁ-
cant anti-tumor and anti-metastatic properties [93] and more
recently the neovastat was also described with anti-inﬂammatory
properties [94]. Furthermore, neovastat not revealed adverse side
effects when applied in clinical uses.
Nitric oxide (NO) belongs to reactive oxygen species (ROS) and is
catalyzed by the nitric oxide synthase (NOS) enzyme family [95,96].
Three NOS isoforms were identiﬁed including neuronal (nNOS),
endothelial (eNOS) and inducible (iNOS) [96,97] and all isoforms
play important biological functions. However, accumulated evi-
dence suggests that NO production by eNOS, may play an important
role in ischemic disorders by promoting neovascularization, and in
tumor angiogenesis through Akt/eNOS signaling pathway activa-
tion. eNOS is thus regarded as a potential therapeutic target, either
through activation in ischemic angiogenesis or through inactivation
in tumor angiogenesis [70,98].
Casein Kinase II (CK2) is a serine/threonine kinase, which cata-
lyzes the phosphorylation of several cytoplasmic and nuclear pro-
teins [99]. CK2 participates in the regulation of multiple biological
process including, survival, proliferation and cellular differentiation
[100]. There is an increasing evidence pointing out that CK2 also
plays an essential role in angiogenesis, either by interaction or
phosphorylation of growth factors or proteins involved in angio-
genesis signaling cascades [101]. Moreover, in tumor cells, the
expression and activity of CK2 is frequently high to ensure cell
growth [102]. CK2 inhibitors used for cancer treatment have found
to be also angiogenesis inhibitors, and CK2 is widely regarded as a
therapeutic target for cancer treatment and tumor angiogenesis
[101].
Protein kinase C (PKC) is another serine/threonine kinase that
acts as an intracellular messenger, with important roles in
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known to be involved in RTKs-mediated angiogenesis signaling
pathways, and its inhibition was shown to promote angiogenesis.
The inhibition of PKC is thus regarded as a novel strategy for
therapeutic angiogenesis, in cases of ischemic cardiovascular dis-
eases [103].3. Antiangiogenic drugs
The development of drugs that act as angiogenic inhibitors has
become essential for the treatment of various types of cancer
(Table 1). The main objective of these antiangiogenic drugs is to
deprive tumor cells of oxygen and nutrients, thus preventing the
formation of new blood vessels and therefore limiting tumor
growth [104]. An extensive, yet non-exhaustive, account of angio-
genesis molecular pathways and targets was presented in chapter 2
(Fig. 1). Still, the majority of drugs in clinical use where developed,
either as RTK inhibitors or as growth factor inhibitors, that activates
the respective RTK (Fig. 2) [104,105]. The explanation for this lack ofFig. 2. Antiangiogenic dtherapeutic targets diversity is probably due to the fact that anti-
angiogenic drugs in clinical use are relatively recent. In fact, it was
only in 2004 that bevacizumab (Avastin) was approved as the ﬁrst
antiangiogenic drug cancer treatment, by the USA Food and Drug
Administration (FDA) [106,107]. Bevacizumab is a monoclonal
antibody that speciﬁcally binds to VEGF, thus preventing it to
interact and activate their RTK receptors [108]. Initially it was
approved as a ﬁrst-line treatment in metastatic colorectal cancer
(CRC) and subsequently for treatment in cervical, non-small cell
lung (NSCL), renal cell and glioblastoma cancers [106,109,110]. With
the increased interest in antiangiogenic drugs, other compounds
were developed over the years (Table 1). These compounds can be
essentially divided in three families: antibodies targeting VEGF or
his membrane RTKs (Bevacizumab and Ramucirumab); small
molecule inhibitors of RTKs (Cabozatinib, Pazopanib, Regorafenib,
Sorafenib, Sunitinib and Vandetanib) and small molecule inhibitors
targeting proteins involved in angiogenesis signaling pathways,
downstream membrane RTKs activation, either directly or byrugs in clinical use.
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[104,106].
Sorafenib was the ﬁrst small RTK inhibitor drug to be developed
and was initially approved against renal cell carcinoma, then
against hepatocellular carcinoma (HCC) and more recently for
differentiated thyroid treatment [111]. Sunitinib soon followed,
being approved for gastrointestinal stromal tumors, rare stomach
cancers and renal cell carcinoma [106,112]. Other RTK inhibitors
approved for antiangiogenic clinical use includes: pazopanib,
approved against advanced renal cell carcinoma and soft tissue
sarcoma; vandetanib, approved against advanced medullary thy-
roid cancer situations that cannot be removed by surgery; carbo-
zoantinib also approved against medullary thyroid cancer and renal
cell carcinoma and vandetanib, approved against medullary thyroid
cancer [107].
Thalidomide is a drug used for several decades for the treatment
of various diseases, but was only approved as an anticancer drug in
2006, being approved against multiple myeloma. The precise
mechanism of its antiangiogenic activity was not yet fully eluci-
dated, although several activities that probably account for its ac-
tivity, including TNF-a, IL-6 expression inhibition and NF-kB and
COX-2 direct inhibition, were observed [113]. Lenalodomide be-
longs to the same type of inhibitors as thalidomine, being also used
against multiple myeloma by inhibiting VEGF expression (Table 1)
[114].
Despite the various molecules involved in the angiogenic pro-
cess, most of these drugs have greater afﬁnity for acting on tyrosine
kinases, particularly the VEGF and respective receptor [104,105].
For example, bevacizumab is a monoclonal antibody that specif-
ically recognize and binds to VEGF, making this growth factor un-
able to activate the receptor [108]. Other inhibitors bind to
receptors, at the surface of endothelial cells, or to other proteins in
the downstream signaling pathways that block their activities
[112].
A common problem when using antiangiogenic drugs is the
common situation of drug resistance. Although initially there is a
positive response to the drugs, and the tumor angiogenesis is
blocked, eventually the tumor acquires resistance and circumvents
the pathway that is blocked, normally the VEGF/VEGFR2 target pair.
Resistance is usually acquired when the tumor is able to growth, by
enabling VEGF/VEGFR-2 independent pathways, thus promoting
tumor angiogenesis [112]. An alternative to overcome the anti-
angiogenic drugs resistance is by their combination with other
conventional therapies, including chemotherapy or radiation [19].
Combined therapies may have a synergistic effect when compared
to the single drug therapies [115]. For example, bevacizumab
sometimes is used with other drugs such as 5-ﬂuorouracil or
chemotherapy, to enhance treatment against various types of
cancers [116].
Another factor to highlight is the toxicity that antiangiogenic
drugs have in the body, contributing to side effects and leading
sometimes to serious injuries [112]. The more common effects
experienced by patients are hypertension, diarrhea, decrease of
white blood cells, fatigue, taste modiﬁcation and appetite reduc-
tion, weight loss, nausea, abdominal pain, skin reactions and hy-
pocalcemia [110,112,117], and more frequent complications include
hepatic toxicity, arterial and venous thrombotic events, gastric
cancer and stroke [110,112]. Still, each drug is administered to
different types of cancer and at distinct doses among patients, they
result in more or fewer side effects in the body. In this sense, it
becomes essential to develop new drugs with lower or no toxicity,
and with the ability to prevent pathological angiogenesis [19]. Re-
searchers have thus focused in antiangiogenic molecules that occur
naturally in plants. These compounds are accessible, have low orminimal toxicity, and have been traditionally used for many years
in the treatment of various diseases [47].4. Natural sources of antiangiogenic compounds
Since primitive societies, plants, herbs and seeds, rich in phy-
tochemicals, were used due to their beneﬁts in human health.
These molecules were shown to present a diverse array of action
mechanisms, including antioxidant activity, enzyme stimulation,
hormonesmimicking and by interferingwith DNA replication [115].
Phytochemicals have thus demonstrated positive effects in health,
especially in cancer prevention [118]. Thereby, secondary plant
metabolites have been considered as potential candidates for in-
hibition of pathological angiogenesis [47,119,120]. In some situa-
tions, in order to increase the beneﬁts/properties of plants,
extractions are conducted. Extractions allow the isolation of active
ingredients, which may subsequently be administered at higher
dosage, in order to obtain higher therapeutic effects [47]. Also,
extracts may contain various phenolic compounds in natural pro-
portions that, through synergistic interactions between them,
complement each other's biological activity [19].4.1. Antiangiogenic potential of extracts from plant and macrofungi
origin
The information regarding the antiangiogenic potential of
bioactive extracts, obtained from different natural sources, is
summarized in Table 2, as well as the test/cell/model used, and
their mechanism of action. Of note, is that methanolic and ethanolic
extractions were the predominantly use methods with natural
sources. The extracts have diverse mechanisms of action, and the
same extract may have different pathways to inhibit angiogenesis.
Different bioactive compounds may present distinct activities at
different molecular levels [19].
In the work developed by Zhu et al. [121], artemisinin was iso-
lated from an ethanolic extraction of Arteminisia annua L. and
evaluated for its angiogenesis inhibition potential. Artemisinin
contributed to a signiﬁcant reduction of PGE2 production in rat
peritoneal cells and human peripheral blood mononuclear cells.
Ghalib et al. [122] studied the antiangiogenic activity in HUVEC's of
aspfalcolide, a compound isolated from a chloroform extract ob-
tained from Asparagus falcatus L. leaves. The results showed a
remarkable inhibitory effect of aspfalcolide on the proliferation
(IC50 1.82 mM), migration and tube formation of human umbilical
vein endothelial cells (HUVECs). Guimar~aes et al. [123] evaluated
the potential of Chamaemelum nobile L. methanolic and aqueous
extracts as angiogenesis inhibitors, through VEGFR-2 inhibition.
The methanolic extract showed superior VEGFR-2 inhibition, when
compared with the aqueous. Huang et al. [124] observed that a
supercritical ﬂuid extract of Croton crassifolius had potent anti-
angiogenic activity on the zebraﬁsh model. They veriﬁed that
cyperenoic acid is the active component present in the extract, and
that this compound interferes with multiple molecular targets
related to angiogenesis, including the growth factors VEGF and
angiopoitein (Ang), and their respective RTKs (VEGFR and Tie-2).
The antiangiogenic potential of Eurycoma longifolia methanol
extract was studied by Al-Salahi et al. [125], using CAM (Chick
chorioallantonic membrane), rat aortic, and HUVEC's assay models.
They observed several angiogenesis inhibition related phenomena,
including inhibition of neovascularization, suppression in sprout-
ing of microvessels and inhibition of proliferation, migration and
differentiation of HUVEC cells. Ahn et al. [95] investigated the
antiangiogenic potential of ethanol extract and subsequent BuOH
fraction of Gastrodia elata Blume, in CAM assay and murine
Table 2
Antiangiogenic extracts from plant and macrofungi origin.
Species Extract type Bioactive compounds Assay/Cells/Model Mechanisms/effects of
antiangiogenic action
References
Plants
Artemisia annua L. Ethanol extract Artemisinin
(sesquiterpene lactone)
Rat peritoneal cells;
PBMC
Inhibition of PGE2 production [121]
Asparagus falcatus Linn Chloroform extract Aspfalcolide
(sesquiterpene lactone)
HUVECs Inhibition of VEGF-induced HUVECs
proliferation, migration and tube
formation
[122]
Chamaemelum nobile L. Methanol extract and
aqueous extract
e Z0-LyteTM Kinase assay
Kit
Inhibition of VEGFR-2 activity [123]
Croton crassifolius Geiseler Supercritical ﬂuid extract
(CO2)
Cyperenoic acid
(terpenes)
Zebraﬁsh Effects on VEGF-A, Ang and
respective receptors
[124]
Eurycoma longifolia Jack Methanol extract e CAM
Rat aortic
HUVECs
Inhibition of neovascularization
Suppression in sprouting of
microvessels
Inhibition of proliferation,
migration and
differentiation
[125]
Gastrodia elata Blume Ethanol extract
Fraction: n-butanol
e Murine macrophage
cell line CAM
Inhibition of NO production and
COX-2
Inhibition of vascular permeability
[95]
Origanum onites L. Essential oil e 5RP7
RATEC
Inhibition of cell viability and
induction of apoptosis;
May block tube formation and
migration
[126]
Pinus halepensis Mill. Lipid fraction
(chloroform/methanol, 2:1)
Neutral lipids, glycolipids,
and phospholipids
EC
CAM
Inhibition of cells tubes formation
Inhibition of blood vessels growth
[127]
Mushrooms
Ganoderma lucidum (Curtis)
P. Karst.
Methanol extract Ganoderic acid F
(lanostane triterpenoid)
HUVECs Inhibition of capillary-like
structures formation
[128]
Phellinus linteus (Berkeley&
Curtis) Teng
Methanol extract
Fractions: methylene
chloride, ethyl acetate, n-
butanol
e HUVECs;
Mice
Inhibition of proliferation,
migration, tube formation and
VEGFR-2 phosphorylation
[129]
Pleurotus tuber-regium
(Rumph. ex Fr.) Singer
Ethanol extract
Fraction: ethyl acetate
Chlorogenic acid and
syringic acid
HUVECs
Zebraﬁsh
Inhibition of VEGF
Decrease of blood vessels
development
[130]
5RP7 e c-H-ras transformed rat embryonic cells; Ang e Angiopoietin; CAM e Chorioallantoic Membrane Assay; COX-2 e Cyclooxygenase-2; EC e Endothelial Cells; Flt-1 or
VEGFR-1 e Vascular Endothelial Growth Factor Receptor 1; HUVEC e Human Umbilical Vein Endothelial cells; NO e Nitric Oxide; PBMC e Human Peripheral Blood
Mononuclear Cells; RATEC e Rate Adipose Tissue Endothelial Cells; VEGF e Vascular Endothelial Growth Factor; VEGF-A e Vascular Endothelial Growth Factor A; VEGFR-2 e
Vascular Endothelial Growth Factor Receptor 2. e Not speciﬁed or described.
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permeability and promotion of NO and COX-2 production. The
antiangiogenic aptitude of the essential oil obtained fromOriganum
onites L. was evaluated by Bostancıoǧlu et al. [126]. The results
show that this essential oil could markedly inhibit cell viability and
induce apoptosis in 5RP7 cells and block formation and migration
in rate adipose tissue endothelial cells (RATEC). Additionally, the oil
demonstrated a higher toxicity against cancer cell (5RP7),
comparatively with healthy cells. In the work developed by Kadria
et al. [127], the antiangiogenic activity of neutral lipids, glycolipids
and phospholipids, obtained from Pinus halepensis Mill. seeds, was
evaluated in vitro using endothelial cells and in vivo using the CAM
assay. Both assays pointed out for strong antiangiogenic activity
through signiﬁcant inhibition of blood vessels growth.
Some studies with mushroom extracts also reveal anti-
angiogenic properties. Nguyen et al. [128] studied ganoderic acid F,
present in a methanolic extract of Ganoderma lucidum, and
observed that ganoderic acid F have a potent inhibitory effect in the
formation of capillary-like structures in HUVEC cells. Lee et al. [129]
evaluated different fractions, obtained from Phellinus linteus
methanolic extract. The results reveal several antiangiogenic
related inhibitory effects, including inhibition of HUVEC cells pro-
liferation, migration and assembly into capillary-like structures.
They observed that the mechanism of action of the extracts
occurred through inhibition of VEGFR-2 phosphorylation. Lin et al.
[130] also studied an ethyl acetate fraction, obtained from themushroom Pleurotus tuber-regium ethanolic extract. The ethyl ac-
etate fraction demonstrated to be rich in phenolics, mainly
chlorogenic and syringic acids. Using the zebraﬁsh model, the ethyl
acetate fraction was shown to inhibit blood vessels development
and, using the HUVEC cells model, this fraction revealed ability to
inhibit VEGF.
Some studies evaluated the anticancer effects of combined
phenolic rich extracts or combined individual phenolic compounds,
in order to overcome pathological angiogenesis. Mertens-Talcott
et al. [131] combined quercetin with ellagic acid and the results
showed a synergistic effect on proliferation reduction, viability and
apoptosis activation in human leukemia cells (MOLT-4). Mertens-
Talcott & Percival [132] investigated the interactions of ellagic
acid, quercetin and resveratrol and the results showed a high
synergistic effect for the ellagic acid/resveratrol combination, in the
induction of apoptosis and reduction of cell growth inMOLT-4 cells.
Bagchi et al. [133] evaluated the in vitro and in vivo efﬁcacy of a
formulation composed by six anthocyanin-rich extracts (fruits of
wild blueberry, bilberry, cranberry, elderberry, and strawberry, and
from raspberry seeds) in antiangiogenic activity. In both in vitro and
in vivo, the combined extracts suppressed important key regulators
of angiogenesis such as TNF-a and VEGF in human keratinocytes,
and signiﬁcantly inhibited NF-kB in mouse hemangioendothelioma
endothelial cells. Other studies developed by Zhou et al. [134] and
Zhou et al. [135], evaluated in vivo the blend between tea and soy
extracts observing the inhibition of angiogenesis, in prostate and
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and coffee, proved to be a potent modulator of NF-kB signaling,
both in vitro in a monocytic cell line, and in vivo in transgenic mice
[136].4.2. Antiangiogenic potential of phenolic compounds
Recently, many studies about phenolic compounds have been
published and have portrayed a picture where they were shown to
interfere, at a molecular level, with a large number of biological
mechanisms [1]. Phenolic compounds were shown to have high
afﬁnity to molecular targets, as diverse as membrane receptors,
protein transporters, transcriptions factors or through gene
expression modulation [53]. Table 3 and Fig. 3 present an overview
of the phenolic compounds that have been reported in the litera-
ture with antiangiogenic activities, through different mechanism/
effects of action.
Kim et al. [65,137], studied the antiangiogenic ability of two
phenolic acids, caffeic and rosmarinic acids, in human retinal
endothelial. The results showed that caffeic acid promotes inhibi-
tion of VEGF-induced proliferation, migration and tube formation,Table 3
Phenolic compounds from commercial sources with antiangiogenic activity.
Phenolic compound Assay/Cells/Model Mechan
Phenolic acids Caffeic acid Human retinal endothelial cells Inhibiti
Ellagic acid BAECs
Smooth muscle cells
Inhibiti
Inhibiti
Rosmarinic acid Human retinal endothelial cells Inhibiti
G2/M p
Flavonoids Acacetin Ovarian cancer cells Decrea
Akt act
Apigenin Human multiple myeloma cells Inhibiti
phosph
Human colorectal cancer cells Anti-pr
Increas
cyclins
p16 do
Human pancreatic cells Inducti
activati
Human pancreatic cancer cells Inhibiti
Cdc37 i
Z0-LyteTM Kinase assay Kit Inhibiti
Casticin and
chrysosplenol D
Rat peritoneal cells; PBMC Suppre
Epigallocatechin-3-
gallate (EGCG)
HUVECs Interfer
Human ﬁbrosarcoma cell line Inhibiti
Genistein Zebraﬁsh Reduct
Retinal cells Reduct
Intestinal epithelium Inhibiti
Kushecarpin D HUVECs Inhibiti
Ability
Luteolin Human pancreatic cancer cells Anti-pr
express
Z0-LyteTM Kinase assay Kit Inhibiti
Quercetin HUVECs;
Zebraﬁsh
Inhibiti
Disrupt
Human lymphocytes Inhibiti
Phenylethanoid Hydroxytyrosol EC Inhibiti
Increas
Decrea
Stilbenes Resveratrol Capillary endothelial cells Inhibiti
BAECs Inhibiti
Human adipose tissue Inhibiti
Retinal pigment epithelium Inhibiti
Akt e Serine-Threonine Kinase; BAECs e Bovine Aorta Endothelial Cells; CK2 e Casein Ki
Endothelial Cells; FGF-2 e Fibroblast Growth Factor 2; GSK-3b e Glycogen Synthase Kin
Endothelial; HSP90/Cdc37 e Heat Shock Protein 90/Cell Division Cycle 37; HUVECs e Hu
LOX-5 e 5-Lipoxygenase; MMP-2eMatrix Metalloproteinase-2; MMP-9eMatrix Metall
Dependent Kinase Inhibitor 1; PBMC e Human Peripheral Blood Mononuclear Cells; P
Necrosis Factor a; VEGF e Vascular Endothelial Growth Factor; VEGFR-2 e Vascular Endowhile rosmarinic acid showed cell cycle related inhibition of cell
proliferation, related to increased levels of p21. Labrecque et al. [23]
studied ellagic acid, having concluded that this phenolic acid in-
hibits phosphorylation of VEGFR-2 and PDGFR, in endothelial and
smooth muscle cells, respectively.
Flavonoids are another group of phenolic compounds that have
been extensively studied as potential chemopreventive agents.
Acacetin was studied by Liu et al. [138] in ovarian cancer cells and
showed a decrease in VEGF activation, through HIF-1a inhibition
and Akt activation; indicating that Akt and HIF-1a are the essential
downstream targets of acacetin for angiogenesis inhibition.
Apigenin is another ﬂavonoid that has been extensively studied.
A study performed by Zhao et al. [102], proved that apigenin ex-
hibits cytotoxicity against human multiple myeloma cells, but not
against normal peripheral bloodmononuclear cells. These activities
were related to proliferation inhibition and apoptosis induction in
human multiple myeloma cells, through CK2 inhibition, Cdc37
reduction and Hsp90 phosphorylation. In a study performed by
Banerjee and Mandal [139], two colorectal cell lines (HT-29 and
HCT-15), were treated with apigenin and the results showed anti-
proliferative and apoptotic effects, together with the increase ofisms/effects of antiangiogenic action References
on of VEGF-induced proliferation, migration and tube formation [137]
onVEGFR-2 phosphorylation
on of VEGF and PDGF receptors phosphorylation
[23]
on of proliferation
hase cell cycle arrest with increase of p21WAF1
[65]
se of VEGF transcriptional activation through HIF-1a inhibition and
ivation
[138]
on of CK2 kinase activity and reduction of Cdc37 and Hsp90
orylation
[102]
oliferative and apoptotic effects
e in p21 levels through a p53 independent pathway and inhibition of
E expression due to large amounts of the active p21and activation of
wn-regulated cyclin D1
[139]
on of cell apoptosis and inhibition of IKK-b-mediated NF-kB
on
[140]
on of the proliferation and migration through inhibition of HSP90/
nteraction
[68]
on of VEGFR-2 activity [123]
ssion of NO, PGE2, and cytokines (VEGF, IL-1b, IL-6 and TNF-a) (*) [121]
ence with formation of VEGFR-2 complex [141]
on of MMP-2 and MMP-9 [27]
ion of VEGF expression [143]
ion of HIF-1a expression [142]
on of the activation of NF-kB and Akt signaling pathways [43]
on of cell proliferation, migration, adhesion, and tube formation;
to induce cell cycle arrest at the G2/M phase (*)
[144]
oliferative and apoptotic effects with signiﬁcantly decreased protein
ion of nuclear GSK-3b and NF-kB
[145]
on of VEGFR-2 activity [123]
on of the VEGFR-2 expression; cell viability and tube formation
formation of intersegmental vessels
[146]
on of COX-2 [53]
on of endothelial cell proliferation, migration and tube formation
e subG1 subpopulation
se MMP2 expression
[147]
on of VEGF and FGF receptors [148]
on of proliferation, migration and tube formation [149]
on of VEGF expression [151]
on of HIF-1a and VEGF expression [150]
nase 2; COX-2 e Cyclooxygenase 2; EC e Endothelial Cells; ECRF-24 e Human Vein
ase 3 beta; HIF-1a e Hypoxia Inducible Factor 1a; HMEC e Human Microvascular
man Umbilical Vein Endothelial Cells; IL-6 e Interleukin 6; IL-1b e Interleukin 1b;
opeptidase 9; NF-kB e Nuclear Factor Kappa B; NOe Nitric Oxide; p21WAF1e Cyclin-
DGF e Platelet-Derived Growth Factor; PGE2 e Prostaglandin E2; TNF-a e Tumor
thelial Growth Factor Receptor-2. *** assay without cells, (*) e From natural sources.
Fig. 3. Phenolic compounds with antiangiogenic activity.
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A. Ribeiro et al. / Cancer Letters 415 (2018) 86e105 97p21 levels and inhibition of cyclins E and D1. In pancreatic cells,
different targets of apigenin were observed and this ﬂavonoid was
shown to interfere with cell proliferation, apoptosis and migration
effects through different mechanism, including inhibition of IKK-b,
NF-kB activation [140] and by HSP90/Cdc37 inhibition [68]. Finally,
Guimar~aes et al. [123] demonstrated, by using an enzymatic assay,
that apigenin was able to inhibit VEGFR-2.
Two ﬂavonoids, casticin and chrysosplenol D, were extracted
from Arteminisia annua L. and studied for their antiangiogenic
proprieties by Zhu et al. [121]. This study showed that these ﬂa-
vonoids are involved in the suppression of various molecules
associated to the angiogenesis process, including NO, PGE2, VEGF,
IL-1b, IL-6 and TNF-a, both in rat peritoneal cells and human pe-
ripheral blood mononuclear cells.
Epigallocatechin-3-gallate (EGCG) is a ﬂavonoid abundantly
found in green tea, that has shown signiﬁcant antioxidant and anti-
cancer activity. Rodriguez et al. [141] reported that ECGC inhibits
the formation of the VEGFR dimer, a process that is essential in
VEGF angiogenesis signaling. Maeda-Yamamoto et al. [27] reported
another effect of EGCG, in human ﬁbrosarcoma cells, where
metastasis development was inhibited by EGCG binding to the
matrix metalloenzymes MMP-2 and MMP-9.
Wang et al. [142], Rathinasamy et al. [143] and Ruiz and Haller
[43] studied the effects of genistein in angiogenesis and veriﬁed,
respectively, a decrease in VEGF expression and consequent inhi-
bition of regenerative caudal ﬁnd in zebraﬁsh, a decrease in HIF-1a
expression in retinal cells and an inhibition of NF-kB and Akt
signaling pathways in intestinal epithelium.
Kushecarpin D is a recently discovered ﬂavonoid, isolated from
the dried root of Sophora ﬂavescens A., a plant known as a medicinal
herb. In a study developed by Pu et al. [144], the antiangiogenic
properties of Kushecarpin D were examined in vitro using HUVEC
cells. The results indicate that this ﬂavonoid showed antiangiogenic
activity, via inhibitory effects on cell proliferation, cell migration,
cell adhesion, and tube formation and the ability to induce cell cycle
arrest at G2/M phase.
Luteolin is another ﬂavonoid abundantly found in various food
sources, its antiangiogenic properties were studied by Johnson and
Mejia [145] and Guimar~aes et al. [123]. These works revealed
interference in the angiogenesis at a molecular level, including,
inhibition of the NF-kB signaling pathway in human pancreatic
cancer cells, and VEGFR-2 activity inhibition.
To ﬁnalize the ﬂavonoid group, Zhao et al. [146] investigated the
antiangiogenic activity of quercetin, both with zebraﬁsh model and
HUVEC cells. Quercetin was shown to disrupt the formation of the
intersegmental vessels, the dorsal aorta and the posterior cardinal
vein in transgenic zebraﬁsh model; and was shown to inhibit cell
viability, VEGFR-2 expression and tube formation in HUVEC cells.
Thus, quercetin was shown to be involved in suppressing, both
in vivo and in vitro, the extracellular signal-regulated VEGFR-2
signaling pathway. Inﬂammation is a process that is tightly linked
with angiogenesis, especially in conditions like rheumatoid
arthritis. Pascual-Teresa et al. [53] studied the potential of quercetin
to stagnate inﬂammation, by inhibition of COX-2 transcription, and
demonstrated that quercetin metabolites were able to downgrade
COX-2 expression.
Fortes et al. [147] investigated the antiangiogenic potential of
hydroxytyrosol, a phenolic compound found in virgin olive oil, in
three different types of endothelial cells including, bovine aorta
endothelial cells (BAEC), umbilical vein endothelial cells (ECRF-24)
and human microvascular endothelial cells (HMEC). This phenolic
compound displayed a diverse set of action mechanisms related to
angiogenesis inhibition. Hydroxytyrosol was shown to inhibit
proliferation, migration and tube formation in the studiedendothelial cells; it affects cell cycle by a remarkable increase in the
subG1 subpopulation, which is indicative of apoptotic cells; and
also decreases the MMP-2 mediated invasive potential of endo-
thelial cells.
Resveratrol is the best studied phenolic compound from the
stilbenes group. Bråkenhielm et al. [148] demonstrated the ability
of resveratrol to inhibit capillary endothelial cell growth and this
inhibition was related to the inhibition of both FGFR and VEGFR
angiogenesis signaling pathway, thru suppression of MAP Kinase
phosphorylation. In a work developed by Igura et al. [149],
resveratrol was shown to inhibit proliferation, migration and tube
formation in BAECs, although the exact molecular mechanism of
action was not studied. Zhang et al. [150] veriﬁed that resveratrol
signiﬁcantly inhibited HIF-1a and VEGF expression, under hypoxia
conditions. Another study performed by Cullberg et al. [151] also
veriﬁed the ability of resveratrol to inhibit key factors in hypoxia
conditions in human adipose tissue, speciﬁcally it was observed
that resveratrol inhibited VEGF expression.
In general, the phenolic compounds have shown signiﬁcant
antiangiogenic properties, and are certainly worth a closer look for
the possible development of new therapies against pathological
and tumor angiogenesis.
4.3. Antiangiogenic potential of other natural compounds
Phenolic compounds are the most extensively studied natural
compounds for their antiangiogenic properties. However, other
compounds, obtained from natural sources, have demonstrated
effectiveness as angiogenesis inhibitors, including alkaloids and
terpenoids (Table 4 and Figs. 4e6), and have also become important
topics of study concerning cancer prevention through inhibition of
angiogenesis.
Pterogynidine is an alkaloid that showed strong antiangiogenic
effects in HUVEC cells. The results demonstrated that this alkaloid
drastically reduced capillary-like structures formation and its ac-
tivity was related to NF-kB inhibition [152]. Punarnavine is another
alkaloid that was shown to inhibit neovascularization in sponge
implant model, using Ehrlich ascites carcinoma model, by sup-
pressing VEGF expression. Using HUVECs cells, punarnavine also
demonstrated inhibition ability of MMP-2 and MMP-9 expression
[153]. In another study, Manu & Kuttan [77] proved the anti-
angiogenic properties of punarnavine in B16F-10 melanoma cells in
mice, by supressing or down regulating the expression of MMP-2,
MMP-9, ERK and VEGF. Zhao et al. [154] studied the anti-
angiogenic potential of total alkaloids present in Rubus alceifolius
poir extract; brieﬂy, the study demonstrated that these compounds
inhibit pathological angiogenesis, through suppression of micro-
vessel, via reducing VEGF expression; and HUVECs cell replication,
by blocking cell cycle G1 to S progression. The results were
conﬁrmed in vivo using the CAM model.
In the terpenoid group, various compounds showed anti-
angiogenic potential. Aescin or b-escin (see Fig. 5), a major active
compound in horse chestnut extract, was able to inhibit angio-
genesis, using the HUVEC cell model and the CAM assay. At a mo-
lecular level, aescin was shown to inhibit angiogenesis by
increasing expression of thrombospondin-1 (TSP-1) and by
decreasing expression of protein kinase C-a (PKC-a) [79].
Other class of terpenoids with antiangiogenic potential are ca-
rotenoids (see Fig. 6). Ganesan et al. [155] studied the anti-
angiogenic potential, and the mechanism of action, of two algal
carotenoids (fucoxanthin and siphonaxanthin), using the HUVEC
cell model. This study showed that both carotenoids suppress FGF-
2 expression. Furthermore, the antiangiogenic inhibition ability of
total carotenoids (b-carotene, b-cryptoxanthin, lutein, zeaxanthin
and retinoic acid), present in maize extract, was established, using
Table 4
Other natural compounds with antiangiogenic potential.
Natural compound Assay/Cell/Model Mechanism/effects of antiangiogenic action Reference
Alkaloids Pterogynidine HUVECs Reduction of NF-kB activity [152]
Punarnavine HUVECs
Ehrlich ascites carcinoma tumor
Inhibition ofMMP-2 andMMP-9 expression
Downregulation of VEGF expression
[153]
B16F-10 melanoma cells Downregulation of MMP-2 and MMP-9,
ERK, VEGF expression
[77]
e HUVECs and CAM Blocking of cell cycle G1/S and inhibition of
VEGF
[154]
Terpenoids Aescin HUVECs and CAM Increase expression of TSP-1, and decrease
expression of PKC-a
[79]
Carotenoids HUVECs Suppression of FGF-2 expression [155]
YSM and CAM e [156]
Celastrol Human glioma cells Suppression of VEGFR expression [157]
Human lung carcinoma (H1299), human embryonic kidney
(A293), human multiple myeloma (U266) and bladder
cancer (253JBV) cell line
Inhibition of TNF-induced and NF-kB
activation
[158]
Escins Ia, Ib, IIa and IIb In mice models e [159]
Furanodiene HUVECs and zebraﬁsh embryos Inhibition of VEGF and suppression of Akt [160]
Polyphyllin D Human microvascular endothelial cell line (HMEC-1) and
Zebraﬁsh embryos
e [161]
Withaferin A Caski human cervical cancer cell line and human hepatoma
(SK-Hep1) cells
Inhibition of MMP-9 activity [163]
HUVECs and CAM Suppression of VEGF expression [162]
# Inhibition of VEGF [164]
HUVECs Inhibition of NF-kB [165]
Withanone and Withaferin A HUVECs and nude mice Downregulation of VEGF and MMP [166]
Akt e Serine-Threonine Kinase; CAM e Chick Chorioallantonic Membrane; ERK e Extracellular Signal-Regulated Kinases; FGF-2 e Fibroblast Growth Factor-2; HUVECs e
Human Umbilical Vein Endothelial Cells; MMP-2 e Matrix Metalloproteinase-2; MMP-9 e Matrix Metalloproteinase-9; NF-kB e Nuclear Factor Kappa B; PKC-a e Protein
Kinase C-a; TNF e Tumor Necrosis Factor; TSP-1 e Thrombospondin-1; VEGF e Vascular Endothelial Growth Factor; VEGFR e Vascular Endothelial Growth Factor Receptor;
YSM e Chick Yolk Sac Membrane; e Not speciﬁed or described; # e not used cells, only molecular docking studies.
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results showed that this extract was an interesting source of ca-
rotenoids, which effectively inhibited the formation of new vessels.
Celastrol (see Fig. 4) is a terpenoid that demonstrated anti-
angiogenic effects, by suppression of VEGFR expression in human
glioma cells, consequently reducing the signal transduction be-
tween VEGF and VEGFR, thus inhibiting endothelial cell prolifera-
tion, migration and differentiation [157]. Other studies proved that
celastrol inhibits angiogenesis through an alternative mechanism,
by inhibiting TNF-a-induced activation of the NF-kB complex [158].
Escins Ia, Ib, IIa and IIb (see Fig. 5), obtained from natural sources,
proved their potential to inhibit the increase of vascular perme-
ability in mice models [159]. Furanodiene (see Fig. 4) is an active
ingredient found in various plants, which was shown to inhibit
angiogenesis in HUVEC cells model, through inhibition of VEGF.
These results were conﬁrmed using the zebraﬁsh model. Fur-
anodiene was also shown to suppress expression of Akt kinase
[160].
Polyphyllin D was another terpenoid studied for its anti-
angiogenic potential. This compound displayed in vitro angiogen-
esis inhibition, by suppressing cell proliferation,migration and tube
formation; and in vivo angiogenesis inhibition by the ability to
impair intersegmental vessels formation in zebraﬁsh embryos
[161].
An extensive study was performed on the antiangiogenic po-
tential of withaferin A [162]. This terpenoid showed ability to block
cell invasion and migration in Caski human cervical cells and in
hepatoma SK-Hep1 cells. This activity was linked to the ability of
withaferin A to decrease MMP-9 activity [163]. Withaferin A also
demonstrated ability to block tube formation in HUVEC cells and in
the CAM assay. This angiogenesis inhibition ability was related to
direct inhibition of VEGF [162]. The hypotheses that withaferin A
promotes angiogenesis inhibition, thru VEGF direct inhibition, was
further demonstrated using a molecular docking approach. In this
study, a rational interaction mode between withaferin A and VEGFwas presented [164]. An alternative mechanism of action of with-
aferin A, obtained from Withania somnifera, was also presented by
another study, where withaferin A was shown to inhibit NF-kB
activity in HUVEC cells [165]. Additionally, Gao et al. [166], stud-
ied the combination of withanone and withaferin A, verifying that
this combination showed signiﬁcant antimigratory and anti-
angiogenic activities, both in vitro or in vivo assays. Furthermore,
the authors demonstrated, by using bioinformatic and biochemical
approaches, that withanone and withaferin A caused down-
regulation of VEGF and MMPs.
Taken together, all the reviewed studies demonstrate that there
are several compounds, obtained from natural sources, which can
be considered for antiangiogenic therapy, or as new drugs for the
development of chemically-related and even more potent anti-
angiogenic compounds. As so, this review synopsizes important
knowledge based on the current state of the art of naturally
occurring angiogenesis inhibitors.
5. Future challenges
Due to their remarkable chemical variety, natural compounds
have attracted considerable attention as potential candidates for
therapeutic use against different pathologies. Special attention has
been payed to naturally occurring anticancer agents, and respective
derivatives, and in the study of the multiple pathways involved in
cancer development [167]. Angiogenesis is an essential process
involved in several diseases, including tumor-associated angio-
genesis. Although angiogenesis is considered a relevant target for
the prevention and treatment of many disorders, the bulk of the
research done so far is focused on tumor angiogenesis, and, as a
consequence, clinically available antiangiogenic drugs are all tar-
geted to tumor angiogenesis [47,168]. Current antiangiogenic drugs
are limited in number, expensive and have shown to induce serious
side effects (Table 1 and Fig. 2). The search for natural products and
natural molecules as potential antiangiogenics, with less toxicity
Fig. 4. Alkaloids and terpenoids with antiangiogenic activity.
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angiogenic therapy [115]. This review describes a wide variety of
natural extracts and molecules (Tables 2e4 and Figs. 3e6) with
angiogenic modulation ability and, when relevant information is
available, the molecular mechanisms underlying the respective
activity are discussed. When comparing the small number of pro-
teins targeted by current antiangiogenic drugs, with the large
number of molecular pathways involved in the complex mecha-
nism of angiogenesis, it is clear to draw the conclusion that there is
still considerable work to be done in order to ﬁnd better and more
diverse antiangiogenic drugs, and natural sources urge to be
explored due to their chemical diversity [47].
The main advantage of natural products, relies on their ability to
be more acceptable to patients, thus more adequate to be admin-
istered orally. As shown in Tables 2e4, natural compounds present
various mechanisms in order to target angiogenesis. Furthermore,
these natural molecules exhibit antiangiogenic activity identical to
the synthetically drugs currently in clinical use [47]. In this sense,
Chatterjee & Bhattacharjee [167] compared the performance of
epigallocatechin gallate and the drug pazopanib, as VEGFR-2 in-
hibitors. The results showed similar effectiveness of the two com-
pounds. Furthermore, the use of phenolic compounds individually,
or combined, has shown to diminish synthetic drugs resistance and
may have therapeutic potential for a broader range of tumor dis-
eases [47].
In spite of the current context, there are still problems that need
to be overcome, to generalize the use of natural compounds in
clinical practice against different pathologies [115]. The mainproblems are related to bioavailability, bioefﬁcacy and biostability
issues, since many natural compounds exhibit low solubility and
low absorption rates. Therefore, only a small amount of the inges-
ted dose reaches the circulation and the desired target location
[115]. Microencapsulation constitutes a possible technique that
may help to surpass these constraints, ensuring a better deliver of
natural compounds to the desired tissue target. Through micro-
encapsulation, natural compounds are incorporated into polymer
matrices enabling better protection [169]. Such processes help to
guarantee the activity of the natural compounds, and to improve
targeting to the desired location [170]. Several studies, conducted
to microencapsulate phenolic compounds, showed enhanced
antiangiogenic effects of these forms [170e172]. Another strategy
to increase the bioavailability, efﬁcacy and stability is discussed by
Wang et al. [47] and Lu et al. [115] consisting on chemical deriva-
tization. Chemical derivatization also called as chemical modiﬁca-
tion correspond at a transformation of chemical compound in
another compound by changing one or more functional groups in
order to modify the speciﬁc characteristics. In this sense, the main
objective is altering reactivity or properties such as solubility,
thermal stability, among others. Thus, with this approach, func-
tional groups are added or removed to the phenolic compounds,
improving its pharmacokinetic proﬁle [47]. The principal objective
of these modiﬁcations is increasing the bioactivity of the phenolic
compounds and consequently problems, such as absorption, can be
overcome and thus favoring their interaction with the speciﬁc
molecules of pathological angiogenesis blocking the reaction chain.
However, these technologies such as microencapsulation or
Fig. 6. Different carotenoids (terpenoids) with antiangiogenic activity.
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studies in order to optimize the antiangiogenic effect.
Pathological angiogenesis occurs when an imbalance of
endogenous proangiogenic and antiangiogenic factors occurs.
Although the focus of angiogenesis-related drug development has
been geared to the discovery of antiangiogenic compounds for use
in pathologies where excessive angiogenesis occurs (cancer, rheu-
matoid arthritis, retinopathy to name a few), an increase interest
has been directed towards the development of proangiogenic drugs
for use in pathologies were insufﬁcient angiogenesis occurs (cor-
onary heart disease, stroke, chronic wounds to name a few) [173].
Given that a number of natural compounds have exhibited proan-
giogenic activity, the approach of explore these compounds in such
applications conﬁgures a promising ﬁeld of research [115].
6. Concluding remarks
All cells need a steady supply of oxygen, nutrients and a way to
remove waste materials, and this is accomplished by an efﬁcient
network by blood vessels. Angiogenesis is a biological process
through which new blood vessels are formed and is essential for
various biological processes. Pathological angiogenesis is related
with the development of various and serious diseases, particularly
cancer. In this case, the angiogenesis is very important for devel-
opment, survival and metastases formation. Angiogenesis is very
complex and involves different and numerous angiogenic factors
and signaling pathways, including growth factors, MMP, cytokines,
arachidonic acid derivatives, transcription factors and cell cycle
related proteins among others. VEGF and his membrane receptor is
the most studied growth factor. Several antiangiogenic drugs have
been developed, and bevacizumab was the ﬁrst one to be used in
therapies applied in vivo to tumor angiogenesis. Still, due to toxicity
and cost constraints of these drugs, the development of new
treatments is becoming highly important. In this context, natural
bioactive compounds, present in various natural products, have
shown high antiangiogenic capacity together with well-being ef-
fects. Compared with currently available antiangiogenic drugs,
plant-derived products may not only have similar therapeutic po-
tential, presenting also clear advantages due to their lower toxicity
and ease way of administration. Also, they can be regarded as
inexpensive solutions, when compared with synthetic counter-
parts. The approach of applying natural compounds in the treat-
ment to angiogenesis-related pathologies is, therefore, a promising
ﬁeld of research. However, novel and effective strategies are
necessary to improve their bioavailability for clinical use.
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